Aemetis, Inc (NASDAQ:AMTX - Free Report) - Equities research analysts at HC Wainwright cut their FY2029 earnings per share estimates for Aemetis in a report released on Friday, August 8th. HC Wainwright analyst A. Dayal now expects that the specialty chemicals company will post earnings of $4.22 per share for the year, down from their prior estimate of $4.23. The consensus estimate for Aemetis' current full-year earnings is ($2.07) per share.
A number of other research analysts have also recently issued reports on the stock. UBS Group lifted their target price on shares of Aemetis from $2.20 to $3.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Ascendiant Capital Markets lifted their target price on shares of Aemetis from $19.00 to $20.00 and gave the company a "buy" rating in a research note on Friday, June 6th.
Get Our Latest Stock Report on AMTX
Aemetis Trading Up 10.3%
NASDAQ AMTX opened at $2.67 on Monday. The stock's 50 day moving average is $2.57 and its two-hundred day moving average is $2.04. The company has a market capitalization of $168.85 million, a price-to-earnings ratio of -1.65 and a beta of 1.49. Aemetis has a 1-year low of $1.22 and a 1-year high of $4.73.
Aemetis (NASDAQ:AMTX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The specialty chemicals company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The business had revenue of $52.24 million during the quarter, compared to the consensus estimate of $78.68 million.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the company. Clear Harbor Asset Management LLC raised its stake in shares of Aemetis by 31.0% in the second quarter. Clear Harbor Asset Management LLC now owns 21,950 shares of the specialty chemicals company's stock valued at $54,000 after acquiring an additional 5,200 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Aemetis by 16.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 38,016 shares of the specialty chemicals company's stock worth $103,000 after buying an additional 5,281 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Aemetis by 128.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company's stock worth $28,000 after buying an additional 5,859 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in Aemetis by 48.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 19,611 shares of the specialty chemicals company's stock worth $49,000 after buying an additional 6,420 shares in the last quarter. Finally, Barclays PLC lifted its holdings in Aemetis by 14.7% during the 4th quarter. Barclays PLC now owns 54,492 shares of the specialty chemicals company's stock worth $146,000 after buying an additional 6,996 shares in the last quarter. Institutional investors own 27.02% of the company's stock.
Aemetis Company Profile
(
Get Free Report)
Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aemetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aemetis wasn't on the list.
While Aemetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.